Australia markets close in 4 hours 31 minutes
Explore/

Most Sold By Hedge Funds

Most Sold By Hedge Funds

10.68k followers31 symbols Watchlist by Yahoo Finance

Follow this list to discover and track the stocks that were sold the most by hedge funds in the last quarter.

Curated by Yahoo Finance

Follow this list to discover and track the stocks that were sold the most by hedge funds in the last quarter.

Background

Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.

Performance

WatchlistChange today1-month return1-year returnTotal return
Most Sold By Hedge Funds----
^GSPC+1.62%+6.89%+16.01%+3809.04%

31 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
BACBank of America Corporation28.98+1.59+5.81%4:00 pm GMT-578.58M60.73M250.70B
CRMsalesforce.com, inc.260.84+3.20+1.24%4:00 pm GMT-55.21M7.84M237.36B
TAT&T Inc.29.23+0.61+2.13%4:04 pm GMT-542.19M38.32M208.29B
BMYBristol-Myers Squibb Company63.22+1.30+2.10%4:00 pm GMT-513.26M10.49M142.86B
RTXRaytheon Technologies Corporation74.36+1.72+2.37%4:00 pm GMT-59.90M8.93M112.93B
SCHWThe Charles Schwab Corporation49.79+1.55+3.21%4:00 pm GMT-59.89M11.83M93.47B
GEGeneral Electric Company10.45+0.38+3.77%4:00 pm GMT-5175.39M110.59M91.54B
UBERUber Technologies, Inc.51.26+1.22+2.44%4:00 pm GMT-516.13M22.16M90.41B
GMGeneral Motors Company46.46+1.69+3.77%4:00 pm GMT-519.19M15.95M66.50B
SNAPSnap Inc.44.29-0.97-2.14%4:00 pm GMT-521.32M35.47M65.99B
PBRPetróleo Brasileiro S.A. - Petrobras10+0.65+6.95%4:00 pm GMT-543.25M22.55M64.77B
ABEVAmbev S.A.2.78+0.04+1.46%4:00 pm GMT-530.34M23.82M43.33B
FCXFreeport-McMoRan Inc.23.11+1.20+5.48%4:02 pm GMT-534.61M19.36M33.58B
PCGPG&E Corporation12.82+0.12+0.94%4:00 pm GMT-520.79M21.07M25.44B
NOKNokia Corporation4.07+0.10+2.52%4:00 pm GMT-525.16M32.84M22.59B
AESThe AES Corporation21.15+0.69+3.37%4:00 pm GMT-55.08M5.25M14.07B
MGMMGM Resorts International28.45+2.30+8.80%4:00 pm GMT-512.05M12.82M14.05B
VICIVICI Properties Inc.26.11+0.02+0.08%4:00 pm GMT-54.53M4.65M14.01B
ALLYAlly Financial Inc.31.07+1.21+4.05%4:00 pm GMT-54.73M5.02M11.62B
LBL Brands, Inc.39.69-0.29-0.73%4:02 pm GMT-54.08M4.35M11.03B
TEVATeva Pharmaceutical Industries Limited9.86+0.25+2.60%4:00 pm GMT-58.38M8.24M10.84B
ACIAlbertsons Companies, Inc.15.9-0.02-0.13%4:00 pm GMT-51.90M3.03M7.52B
PEParsley Energy, Inc.13.91+0.79+6.02%4:00 pm GMT-57.90M9.10M5.74B
MROMarathon Oil Corporation6.45+0.28+4.54%4:00 pm GMT-541.21M28.58M5.09B
FSRFisker Inc.15.97--4:00 pm GMT-510.54M10.07M4.43B
UNVRUnivar Solutions Inc.18.71+0.56+3.09%4:00 pm GMT-51.97M1.84M3.16B
GBGlobal Blue Group Holding AG11.1+0.08+0.73%4:00 pm GMT-520.66k64.16k1.86B
GNUSGenius Brands International, Inc.1.35+0.11+8.87%4:00 pm GMT-558.03M25.50M346.18M
VALPQValaris plc0.082+0.00+0.99%3:59 pm GMT-52.08M2.77M16.36M
NEBLQNoble Holding Corporation plc0.0357+0.00+2.59%3:57 pm GMT-57.79M2.10M8.96M
  • The Dow hitting 30,000 may just be the start, hints investing legend
    Editor's pick
    Yahoo Finance

    The Dow hitting 30,000 may just be the start, hints investing legend

    Wall Street veteran Byron Wien shares his market outlook on the day the Dow climbed beyond 30,000 for the first time.

  • Bull Moves: Analysts Just Upgraded These 3 Hot Stocks
    TipRanks

    Bull Moves: Analysts Just Upgraded These 3 Hot Stocks

    The world’s largest asset manager is impressed with the market’s recent gains, and it has made that sentiment clear by upgrading US stocks. In its recent reassessment of conditions in the American financial markets, investment giant BlackRock issued a general upgrade for Wall Street. This wasn’t an upgrade on particular stocks, but on the US market as a whole.Explaining the move, the BlackRock note points out that the daily COVID news is just noise – the real news is on the vaccine front, where at least two effective vaccines are just months away from public distribution. A viable vaccine for the coronavirus disease will push us back to normal conditions, and boost investors’ mood immeasurably. Hence, the upgrade.“We upgrade US equities to overweight, with a preference for quality large caps riding structural growth trends, as well as smaller companies geared to a potential cyclical upswing,” BlackRock said. The company expects to see a cyclical upturn in the US economy in 2021, as the coronavirus crisis fades into the background and the political landscape moves back to pre-Trump patterns.The general upgrade by BlackRock was only one sign of confidence in the US markets. Several of Wall Street’s research firms have also been issuing upgraded stances, taking a micro view and applying their revisions to specific equities. We’ve pulled up three from the TipRanks database, and found that they fit BlackRock’s preference: mid- to large-cap companies with established positions in the market.Cleveland-Cliffs, Inc. (CLF)We’ll start with Cleveland-Cliffs, an Ohio based mining company. Cleveland-Cliffs specializes in iron production, and has four active mines in Minnesota and Michigan. The company focuses on mining, beneficiating, and pelletizing the ore, a process that produces iron pellets in a variety of grades fit for blast furnace smelting, steelmaking, and alloying. Cleveland-Cliffs is capable, on its own, of producing more than 40% of the total US capacity in iron pellets. It also produces flat-rolled carbon, stainless steel, and electrical steel products.As the economy ramps back up, recovering from the deepest coronavirus hits, Cleveland-Cliffs’ revenues have been rising. The company’s top line has grown since the first quarter of 2020, posting sequential gains in both Q2 and Q3. The third quarter number, at $1.65 billion, was in line with analyst expectations, and came in far ahead of the $555.6 million posted in the year-ago quarter.The share price has mirrored this recovery. The stock hit bottom back in mid-March, at just $3.14 per share. Since then, it has shown impressive growth. The shares have fully recouped those mid-winter losses, and are now trading up 32% year-to-date.GLJ Research analyst Gordon Johnson sees Cleveland-Cliffs gaining as the pandemic draws back and its customers resume normal economic activity. To this end, the analyst upgraded CLF from Hold to Buy, and his $15.80 price target suggests it has a 46% upside in the coming year. (To watch Johnson’s track record, click here)“US automotive production has rebounded to pre-pandemic levels, a clear positive for Cliffs, as ~27% of its (soon-to-be) steel demand comes from that sector. Even oil/gas rig counts, while still down sharply y/y, appear to have turned a corner in terms of growth. Moreover, our checks indicate potential delays to supply additions. As we see it, these dynamics, which have sent US HRC prices to near $734/short ton last week, have the potential to keep … price levels sustained into 2021,” Johnson stated.Overall, the Moderate Buy consensus rating on CLF is based on an even split; the stock has 3 Buys and 3 Holds on record. However, its recent share appreciation has pushed it above the average price target. The shares are selling for $10.85, while the average target remains $10.09 for now. (See CLF stock analysis on TipRanks)General Electric (GE)Also upgraded today is General Electric. The company once boasted one of the most famous marketing jingles in advertising – “We bring good things to life” – referring to its position as a major manufacturer of home appliances. Today, this multinational conglomerate has its hands in a wide variety of manufacturing sectors, from aviation to electrical power to renewable energy.GE’s stock has been on an upward trajectory since the company released the Q3 earnings report at the end of October. The results – while down year-over-year – showed solid sequential gains and came in above analyst expectations. At the top line, revenue grew from $17.7 billion to $19.4 billion, while EPS, which had been negative in Q2, turned positive and came in at 6 cents per share. The EPS forecast had been for a 6-cent loss. Christopher Glynn, 5-star analyst with Oppenheimer, sees GE in a fundamentally sound position. The analyst upgraded GE, taking it from Neutral to Outperform (i.e. Buy). His $12 price target implies an upside potential of ~15% for the next 12 months. (To watch Glynn’s track record, click here)Glynn commented, “Our Outperform rating reflects view of more pointed read-through of cost reduction initiatives resulting in early stages of clearer breadth of operating momentum across the segments. We believe working capital performance could surprise to the upside in 2021, considering GE working through widespread facility consolidations and managing working capital amidst that during2020 (and continuing).""We also like the extended duration of the debt structure and strong liquidity, now affording a backdrop toemerge from the Aviation downturn in a position of resilience,” the analyst noted. GE’s recent share appreciation has pushed the stock price above the average price target. The stock is currently trading at $10.45 per share – but the average target is $9.29. It remains to be seen if Glynn’s upgrade and higher target are the start of general reassessment of this stock. For now, GE has a Moderate Buy analyst consensus rating, based on 13 reviews that include 8 Buys and 5 Holds. (See GE stock analysis at TipRanks)Wells Fargo (WFC)Last but not least is Wells Fargo, whose $118 billion market cap makes it the world’s fourth largest bank. It is also the fourth largest in the US, boasting nearly $2 trillion in total assets. Wells Fargo offers a full range of banking services, for residential and commercial customers as well as major companies and investment firms.The corona crisis of 2020 hit Well Fargo hard, and the bank’s share price has still not recovered from the fall it took in February and March of this year. Revenues have been regaining ground through the past nine months, but slowly – the Q3 number, $18.7 billion, was up a full billion dollars from Q1, but still down from 4Q19, the last pre-corona quarter. The Fed’s low interest rate policy has put a damper on bank profits, and Wells Fargo’s net interest income for the Q3 was down 19% year-over-year to $9.4 billion.Despite these headwinds, Raymond James analyst David Long is turning bullish on WFC shares. In a research note issued today, the analyst double-upgraded WFC from Underperform (i.e. Sell) to Outperform (i.e. Buy) along with a $32 price target. (To watch Long’s track record, click here)In his comments on the stock, Long notes the composition of Wells Fargo’s loan portfolio as a structural strength: “We expect Wells Fargo's credit performance during this credit cycle to perform better than its peers due to its large exposure to residential real estate loans, which account for 35% of its total loan portfolio (compared to peers at 23%), as home prices have held up well. Furthermore, its exposure to hotel (1.3% of loans) and entertainment (1.0%) are well below levels of its peers.”the analyst concluded, "With the worst likely in the past, we now believe that its pretax pre-provision income has troughed, revenue is nearing a bottom, a multi-year expense rationalization initiative can finally be taken on, and repurchase activity can return in the near future."All in all, the analyst consensus rating here is a Moderate Buy, based on 14 reviews which include 7 Buys, 6 Holds, and 1 Sell. The average price target, however, reflects Wall Street’s caution here; at $29.08 it suggests only limited growth -- 1.64% to be precise. (See WFC stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Celsion, Citigroup, Raytheon, Intercept Pharmaceuticals and Encourages Investors to Contact the Firm
    GlobeNewswire

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Celsion, Citigroup, Raytheon, Intercept Pharmaceuticals and Encourages Investors to Contact the Firm

    NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Celsion Corporation (NASDAQ: CLSN), Citigroup, Inc. (NYSE: C), Raytheon Technologies Corporation (NYSE: RTX), and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Celsion Corporation (NASDAQ: CLSN) Class Period: November 2, 2015 to July 10, 2020Lead Plaintiff Deadline: December 28, 2020Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment. On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.The complaint, filed on October 29, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.For more information on the Celsion class action go to: https://bespc.com/cases/CLSNCitigroup, Inc. (NYSE: C) Class Period: January 15, 2016 to October 12, 2020Lead Plaintiff Deadline: December 29, 2020The Class Period begins on February 25, 2017, following the Company’s submission of its 2016 Annual Report to the SEC. In that filing, and throughout the Class Period, Citi assured investors that there were no significant deficiencies or material weaknesses in the Company’s internal controls. When faced with periodic regulatory penalties for noncompliance, the Company continued to assure investors that the specific deficiencies at issue were being remediated promptly and that internal controls and regulatory compliance were a top priority at Citi. In particular, Citi assured investors that it satisfied all regulatory requirements and maintained adequate internal controls, data governance, compliance risk management, and enterprise risk management.In reality, during the Class Period and unbeknownst to investors, Citi’s internal controls and risk management capabilities suffered from “serious” and “longstanding” inadequacies that exposed the Company to massive regulatory penalties and will cost significantly more than $1 billion to remediate. Specific control failures about which Citi executives were warned remained unresolved for years and the Company’s culture of non-compliance was so widespread that Citi’s CEO, Defendant Michael Corbat, exhorted employees in an internal memo that regulatory compliance required more than “checking boxes.”The truth began to emerge on September 14, 2020, when reports surfaced that regulators were preparing to reprimand Citi for failing to improve its risk-management systems.That disclosure caused the price of Citi’s stock to decline $2.85 per share, from $51.00 to $48.15, erasing $5.91 billion in shareholder value.After the market closed on September 14, 2020, an internal memo sent to Citi employees revealed for the first time the Company’s disregard for adequate internal controls and regulatory compliance.As a result, the price of Citi’s stock declined an additional $3.34 per share, from $48.15 to $44.81, erasing $6.93 billion in shareholder value.Then, on October 13, 2020, Citi reported earnings for the third quarter of 2020, and disclosed that the Company’s expenses increased during the third quarter by 5%, to $11 billion, due to an increase in costs including a $400 million fine, investments in infrastructure, and other remediation costs related to control deficiencies.These disclosures caused Citi’s stock price to decline by $2.20 per share, from $45.88 to $43.68, erasing $4.57 billion in shareholder value.For more information on the Citigroup class action go to: https://bespc.com/cases/CRaytheon Technologies Corporation (NYSE: RTX) Class Period: February 10, 2016 to October 27, 2020Lead Plaintiff Deadline: December 29, 2020On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2020 (the “3Q20 Report”). The 3Q20 Report announced the DOJ Investigation, stating in pertinent part: “On October 8, 2020, the Company received a criminal subpoena from the DOJ seeking information and documents in connection with an investigation relating to financial accounting, internal controls over financial reporting, and cost reporting regarding Raytheon Company’s Missiles & Defense business since 2009.”On this news, the price of Raytheon shares fell $4.19 per share, or 7%, to close at $52.34 per share on October 28, 2020, on unusually heavy trading volume, damaging investors.The complaint, filed on October 30, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.For more information on the Raytheon class action go to: https://bespc.com/cases/RTXIntercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Class Period: September 28, 2019 to October 7, 2020Lead Plaintiff Deadline: January 4, 2021Intercept’s lead product candidate is Ocaliva (obeticholic acid (“OCA”)), a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (“PBC”), a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults. The Company is also developing OCA for various other indications, including nonalcoholic steatohepatitis (“NASH”).On May 22, 2020, Intercept reported that the FDA “has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company’s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed” to “accommodate the review of additional data requested by the FDA that the company intends to submit within the next week.”On this news, Intercept’s stock price fell $11.18 per share, or 12.19%, to close at $80.51 per share on May 22, 2020.On June 29, 2020, Intercept issued a press release announcing that the FDA had issued a Complete Response Letter (“CRL”) rejecting the Company’s NDA for Ocaliva for the treatment of liver fibrosis due to NASH.On this news, Intercept’s stock price fell $30.79 per share, or 39.73%, to close at $46.70 per share on June 29, 2020.Then, on October 8, 2020, news outlets reported that Intercept was “facing an investigation from the [FDA] over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”On this news, Intercept’s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020.The complaint, filed on November 5, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (ii) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.For more information on the Intercept class action go to: https://bespc.com/cases/ICPT-2About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com